Calcium Microcrystalline Hydroxyapatite - Douglas Laboratories
Calcium Microcrystalline Hydroxyapatite - Douglas Laboratories
Calcium Microcrystalline Hydroxyapatite - Douglas Laboratories
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Douglas</strong><br />
<strong>Laboratories</strong> ®<br />
Product Data<br />
<strong>Calcium</strong> <strong>Microcrystalline</strong><br />
<strong>Hydroxyapatite</strong><br />
DESCRIPTION<br />
<strong>Calcium</strong> <strong>Microcrystalline</strong> <strong>Hydroxyapatite</strong>, provided<br />
by <strong>Douglas</strong> <strong>Laboratories</strong> ® , supplies 250 mg of<br />
elemental calcium from 1,000 mg of microcrystalline<br />
hydroxyapatite(MCHC), a bioavailable source of<br />
calcium derived from whole bone.<br />
FUNCTIONS<br />
The adult human body contains approximately 1,200 g<br />
of calcium, about 99% of which is present in the<br />
skeleton. Bone is constantly turning over, a continuous<br />
process of formation and resorption. In children and<br />
adolescents, the rate of formation of bone mineral<br />
predominates over the rate of resorption. In later life,<br />
resorption predominates over formation. Therefore, in<br />
normal aging, there is a gradual loss of bone.<br />
Osteoporosis, a condition of reduced bone mineral<br />
density that can increase risk of fractures, affects a large<br />
proportion of the elderly in developed countries.<br />
Caucasian and Asian women typically have low peak<br />
bone densities, and therefore, are at the greatest risk of<br />
developing osteoporosis. It is generally accepted that<br />
obtaining enough dietary calcium throughout life can<br />
significantly decrease the risk of developing<br />
osteoporosis. Among other factors, such as regular<br />
exercise, gender and race, calcium supplementation<br />
during childhood and adolescence appears to be a<br />
prerequisite for maintaining adequate bone density later<br />
in life. But even elderly osteoporotic patients can benefit<br />
significantly from supplementation with dietary<br />
calcium.<br />
<strong>Calcium</strong> <strong>Microcrystalline</strong> <strong>Hydroxyapatite</strong> provides a<br />
highly beneficial source of dietary calcium together with<br />
other nutrients that assist in the maintenance of healthy<br />
bone structure and function. For example, boron affects<br />
the composition, structure, and strength of bone. It<br />
appears to be necessary for calcium and magnesium<br />
absorption, their adequate renal reabsorption, and their<br />
incorporation into the bone matrix. Boron is absorbed at<br />
about 90% efficiency and is rapidly distributed among<br />
the tissues.<br />
INDICATIONS<br />
<strong>Calcium</strong> <strong>Microcrystalline</strong> <strong>Hydroxyapatite</strong> tablets may<br />
be a useful dietary supplement for individuals who wish<br />
to increase their intake of calcium and other nutritional<br />
factors for the maintaining of healthy bone function.<br />
FORMULA (#83018)<br />
Each Tablet Contains:<br />
<strong>Calcium</strong> <strong>Microcrystalline</strong> <strong>Hydroxyapatite</strong>1,000 mg<br />
Yielding:<br />
<strong>Calcium</strong> ........................................................250 mg<br />
Phosphorus ...................................................130 mg<br />
Protein ..........................................................250 mg<br />
(as Collagen Glycosaminoglycans and Substituent<br />
Amino Acids)<br />
Boron(as Boron Aspartate) ...........................2.5 mg<br />
SUGGESTED USE<br />
Adults take 2-4 tablets daily with meals or as directed<br />
by a physician.<br />
SIDE EFFECTS<br />
No adverse side effects reported.<br />
STORAGE<br />
Store in a cool, dry place, away from direct light.<br />
Keep out of reach of children.<br />
REFERENCES<br />
Barger-Lux MJ, Heaney RP. The role of calcium intake in preventing bone<br />
fragility, hypertension, and certain cancers. J Nutr 1994;124:1406S-1411S.<br />
Benderdour M, Bui-Van T, Dicko A, Belleville F. In vivo and in vitro effects of<br />
boron and boronated compounds. J Trace Elem Med Biol 1998;12:2-7.<br />
O’Brien KO. Combined calcium and vitamin D supplementation reduces bone<br />
loss and fracture incidence in older men and women. Nutr Rev 1998;56:148-50.<br />
Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline<br />
hydroxyapatite compound (‘Ossopan’) in the prevention of osteoporosis due to<br />
cortcosteroid therapy. Curr Med Res Opin 1984;8:734-42.Uusi-Rasi K, Sievanen<br />
H, Pasanen M, Oja P, Vuori I. Maintenance of body weight, physical activity and<br />
calcium intake helps preserve one mass in elderly women. Osteoporos Int<br />
2001;12(5):373-9.<br />
(continued on reverse)
These statements have not been evaluated by the Food and Drug Administration.<br />
This product is not intended to diagnose, treat, cure, or prevent any disease.<br />
Distributed by<br />
<strong>Douglas</strong> <strong>Laboratories</strong><br />
552 Newbold St., London, Ontario N6E 2S5<br />
Phone: 866.856.9954 Fax: 888.220.9441<br />
Email: info@douglaslabs.ca Website: www.douglaslabs.ca<br />
2003 <strong>Douglas</strong> <strong>Laboratories</strong>, INC. All Rights Reserved
Change language